Heartseed, Inc. (JP:219A)
:219A
Want to see JP:219A full AI Analyst Report?
Top Page
Heartseed, Inc.
(219A)
Select Model
Select Model
Rating:63Neutral
Price Target:
¥1,707.00
▼(-5.38% Downside)
Action:Reiterated
Date:02/19/26
The score is driven primarily by the FY2025 financial turnaround (profitability and positive free cash flow) and a strong, low-leverage balance sheet. This is tempered by the prior multi-year loss/cash-burn history and an expensive valuation (high P/E), while technicals are neutral-to-modestly supportive but still below the 200-day trend.
Positive Factors
Conservative balance sheet / extremely low leverage
Near-zero debt and a large equity base provide durable financial flexibility for a biotech in development. Low leverage reduces insolvency risk, preserves optionality for long R&D cycles, and allows management to fund clinical programs or partnerships without urgent refinancing pressure.
Negative Factors
Multi-year losses and historical cash burn
A history of multi-year losses and cash burn indicates execution and earnings volatility that can persist through development cycles. Such legacy deficits mean management must sustain operational improvements or face renewed funding needs, making long-term planning sensitive to setbacks.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet / extremely low leverage
Near-zero debt and a large equity base provide durable financial flexibility for a biotech in development. Low leverage reduces insolvency risk, preserves optionality for long R&D cycles, and allows management to fund clinical programs or partnerships without urgent refinancing pressure.
Read all positive factors
Heartseed, Inc. (219A) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥36.67B
Dividend YieldN/A
Average Volume (3M)738.74K
Price to Earnings (P/E)36.2
Beta (1Y)1.17
Revenue GrowthN/A
EPS GrowthN/A
CountryJP
Employees39
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)25.93
Shares Outstanding22,874,200
10 Day Avg. Volume469,170
30 Day Avg. Volume738,736
Financial Highlights & Ratios
PEG Ratio-2.00
Price to Book (P/B)5.17
Price to Sales (P/S)12.93
P/FCF Ratio37.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-94.5
Revenue Forecast (FY)¥451.00M
Heartseed, Inc. Business Overview & Revenue Model
Company Description
Headquartered in Tokyo, Japan, Heartseed, Inc. was established on November 30, 2015, by Keiichi Fukuda, Takumi Akiyama, Toshiharu Furukawa, and Yutaro Kasai. The company specializes in the development and advancement of cardiac regenerative medicine....
How the Company Makes Money
Heartseed, Inc. generates revenue through partnerships with pharmaceutical and biotech companies, offering licensing agreements for its proprietary technologies and products under development. Additional income sources include research and develop...
Heartseed, Inc. Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
86
Very Positive
Cash Flow
67
Positive
| Breakdown | Oct 2025 | Oct 2024 | Oct 2023 | Oct 2022 |
|---|---|---|---|---|
Income Statement | ||||
| Total Revenue | 3.03B | 873.61M | 344.73M | 499.06M |
| Gross Profit | 3.03B | 0.00 | 0.00 | 0.00 |
| EBITDA | 278.71M | -996.98M | -1.45B | -1.46B |
| Net Income | 163.38M | -812.73M | -1.47B | -1.41B |
Balance Sheet | ||||
| Total Assets | 8.14B | 7.07B | 5.72B | 4.94B |
| Cash, Cash Equivalents and Short-Term Investments | 7.34B | 5.30B | 4.59B | 3.99B |
| Total Debt | 890.00K | 5.39M | 11.58M | 30.98M |
| Total Liabilities | 571.35M | 444.34M | 450.19M | 208.45M |
| Stockholders Equity | 7.57B | 6.62B | 5.27B | 4.73B |
Cash Flow | ||||
| Free Cash Flow | 1.05B | -1.36B | -1.13B | -1.92B |
| Operating Cash Flow | 1.08B | -1.34B | -797.93M | -1.92B |
| Investing Cash Flow | 72.64M | -67.13M | -425.69M | -994.00K |
| Financing Cash Flow | 375.76M | 2.12B | 1.85B | -22.16M |
Heartseed, Inc. Technical Analysis
Neutral
1804.00
Price Trends
1741.84
Negative
1829.41
Negative
2086.59
Negative
Market Momentum
-41.72
Negative
46.82
Neutral
55.64
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:219A, the sentiment is Neutral. The current price of 1804 is above the 20-day moving average (MA) of 1583.55, above the 50-day MA of 1741.84, and below the 200-day MA of 2086.59, indicating a neutral trend. The MACD of -41.72 indicates Negative momentum. The RSI at 46.82 is Neutral, neither overbought nor oversold. The STOCH value of 55.64 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:219A.
Heartseed, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | ¥41.78B | 12.78 | ― | 2.53% | 1.74% | 41.32% | |
63 Neutral | ¥36.67B | 36.18 | ― | ― | ― | ― | |
60 Neutral | ¥483.65B | 15.34 | ― | 0.93% | 6.74% | 6.60% | |
54 Neutral | ¥14.61B | 13.21 | ― | 2.32% | 8.01% | -15.21% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | ¥5.87B | -52.76 | ― | 2.65% | 11.78% | 86.75% | |
41 Neutral | ¥7.41B | -4.83 | ― | ― | ― | 32.31% |
* Healthcare Sector Average
JP:219A
Heartseed, Inc.
1,603.00
-2,712.00
-62.85%
JP:2796
Pharmarise Holdings Corp.
500.00
27.72
5.87%
JP:3349
COSMOS Pharmaceutical Corporation
6,076.00
-2,937.26
-32.59%
JP:4350
Medical System Network Co., Ltd.
484.00
37.60
8.42%
JP:4931
Shinnihonseiyaku Co., Ltd.
1,952.00
-252.52
-11.45%
JP:190A
Chordia Therapeutics Inc.
97.00
-137.00
-58.55%
Heartseed, Inc. Corporate Events
Heartseed doses first patient in EMERALD trial of HS-005 for dilated cardiomyopathy
Jun 12, 2026
Heartseed Inc. has begun dosing patients in its domestic Phase I/II EMERALD clinical trial of HS-005, an allogeneic iPS cell-derived cardiomyocyte spheroid therapy administered via catheter, in patients with heart failure caused by dilated cardiom...
Heartseed Advances HS-001 Heart Failure Therapy Toward Japan Approval After Positive Trial Readout
Jun 1, 2026
Heartseed Inc. reported results from its Phase I/II LAPiS clinical trial of HS-001, an allogeneic iPS cell-derived cardiomyocyte spheroid therapy for severe ischemic heart failure, confirming that the study’s primary safety endpoint was met ...
Heartseed Narrows Quarterly Loss but Projects Deeper Full-Year Deficit
May 15, 2026
Heartseed Inc. reported non-consolidated net sales of ¥465 million for the three months ended March 31, 2026, with an operating loss of ¥75 million and a net loss of ¥58 million, narrowing per-share losses to ¥2.54. The company...
Heartseed launches post-delivery RSU plan to align board pay with shareholder value
Apr 16, 2026
Heartseed Inc. has approved the grant of post-delivery restricted stock units to three board directors, excluding independent and non-executive members, under a stock-based compensation plan authorized at its recent shareholder meeting. The initia...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.